From GlobeNewswire: 2024-04-29 04:00:00

The global market for meningococcal vaccines is projected to reach USD 7.8 billion by 2032, with 1.2 million cases of invasive meningococcal disease reported annually. The surge in infections is attributed to factors like population growth and international travel, leading to increased urgency for vaccination as a preventive measure.

Combination vaccines are expected to rise in popularity due to their benefits of simplified schedules, improved compliance, and cost-effectiveness. These vaccines offer comprehensive protection against multiple serogroups of Neisseria meningitidis, streamlining the vaccination process and driving market growth.

The Menactra vaccine segment is anticipated to grow substantially until 2032, thanks to its efficacy in preventing invasive meningococcal disease caused by various serogroups. Research efforts to expand its indication to cover additional serogroups could further boost its market presence in the coming years.

Asia Pacific is set to dominate the regional landscape for meningococcal vaccines through 2032, driven by increased awareness and immunization programs in countries like China and India. Novel vaccine delivery technologies and partnerships between pharmaceutical companies and governments are expected to accelerate market growth in the region.



Read more at GlobeNewswire: Meningococcal Vaccines Market to hit USD 7.8 Bn by 2032,